Wall Street analysts expect that Myovant Sciences Ltd (NASDAQ:MYOV) will report earnings per share (EPS) of ($0.38) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Myovant Sciences’ earnings, with the lowest EPS estimate coming in at ($0.38) and the highest estimate coming in at ($0.37). The company is scheduled to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Myovant Sciences will report full year earnings of ($1.54) per share for the current financial year, with EPS estimates ranging from ($1.55) to ($1.54). For the next financial year, analysts expect that the business will report earnings of ($1.66) per share. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Myovant Sciences.

Several research analysts have weighed in on MYOV shares. Zacks Investment Research lowered shares of Myovant Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, May 3rd. Evercore ISI started coverage on shares of Myovant Sciences in a research note on Wednesday. They set an “outperform” rating for the company. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $18.20.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BB Biotech AG raised its position in Myovant Sciences by 0.4% in the second quarter. BB Biotech AG now owns 3,317,171 shares of the company’s stock valued at $38,811,000 after buying an additional 14,336 shares during the last quarter. RA Capital Management LLC raised its position in Myovant Sciences by 19.6% in the second quarter. RA Capital Management LLC now owns 2,807,550 shares of the company’s stock valued at $32,848,000 after buying an additional 459,128 shares during the last quarter. Norges Bank acquired a new position in Myovant Sciences during the fourth quarter valued at approximately $9,763,000. Voya Investment Management LLC raised its position in Myovant Sciences by 5.4% in the second quarter. Voya Investment Management LLC now owns 421,397 shares of the company’s stock valued at $4,931,000 after buying an additional 21,478 shares during the last quarter. Finally, Eventide Asset Management LLC acquired a new position in Myovant Sciences during the first quarter valued at approximately $3,463,000.

Myovant Sciences (NASDAQ:MYOV) traded up 13.96% during midday trading on Friday, hitting $13.14. 80,057 shares of the company were exchanged. The stock’s market capitalization is $792.08 million. Myovant Sciences has a 1-year low of $9.92 and a 1-year high of $15.50. The stock has a 50 day moving average of $11.20 and a 200-day moving average of $11.79.

TRADEMARK VIOLATION WARNING: “-$0.38 EPS Expected for Myovant Sciences Ltd (MYOV) This Quarter” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/08/18/0-38-eps-expected-for-myovant-sciences-ltd-myov-this-quarter.html.

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Get a free copy of the Zacks research report on Myovant Sciences (MYOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.